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Abstract Centrosomal protein 55 (CEP55) is a cell cycle regu-
lator implicated in development of certain cancers. However,
characteristics of CEP55 expression and its clinical/prognostic
significance are unclear in human epithelial ovarian carcinoma
(EOC). Therefore, we investigated the expression and
clinicopathological significance of CEP55 in patients with EOC
and its role in regulating invasion and metastasis of ovarian cell
lines. CEP55 mRNA and protein expression levels were detected
by quantitative real-time PCR (qRT-PCR), Western blotting, and
immunohistochemistry (IHC). Potential associations of CEP55
expression scores with clinical parameters and patient survival
were evaluated. CEP55 function was investigated further using
RNA interference, wound healing assay, transwell assay, immu-
nofluorescence analysis, qRT-PCR, andWestern blotting. CEP55
was significantly upregulated in ovarian cancer cell lines and
lesions compared with normal cells and adjacent noncancerous
ovarian tissues. In the 213 EOC samples, CEP55 protein levels
were positively correlated with clinical stage (P<0.001), lymph
node metastasis (P<0.001), intraperitoneal metastasis (P<0.001),
tumor recurrence (P<0.001), differentiation grade (P<0.001), re-
sidual tumor size (P<0.001), ascites see tumor cells (P=0.020),
and serum CA153 level (P<0.001). Moreover, patients with ab-
errant CEP55 protein expression showed tendencies to receive
neoadjuvant chemotherapy (P<0.001) and cytoreductive surgery
(P=0.020). By contrast, no significant correlation was detected
between the protein levels and patient age, histological type, or
serum CA125, CA199, CA724, NSE, CEA, and β-HCG levels.
Patients with high CEP55 protein expression had shorter overall
survival and disease-free survival compared with those with low
CEP55 expression. Multivariate analysis implicated CEP55 as an
independent prognostic indicator for EOC patients. Additionally,
downregulation of CEP55 in ovarian cancer cells remarkably
inhibited cellular motility and invasion. Aberrant CEP55 expres-
sion may predict unfavorable clinical outcomes in EOC patients
and play an important role in regulating invasion in ovarian cancer
cells. Thus, CEP55 may serve as a prognostic marker and thera-
peutic target for EOC.
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Introduction
Ovarian cancer is one of the most lethal gynecologic malignan-
cies and is the leading cause of gynecological cancer death [1].
There were 204,000 new cases and 125,000 deaths estimated
worldwide in 2011 [2]. Although advances in surgery and new
chemotherapy regimens have resulted in downward trends of the
incidence and mortality of ovarian cancer over the last few de-
cades, it is still associated with the highest mortality rate among
all gynecological malignancies worldwide [3]. One reason for
the lethality of ovarian cancer is that the majority of women are
undiagnosed until advanced International Federation of
Gynecology and Obstetrics (FIGO) stages (III or IV) where the
cancer has spread beyond the pelvis, which leads to an unfavor-
able prognosis [4]. Several traditional clinical variables, including
surgical stage, volume of residual tumor after primary surgery,
and histologic grade play important roles in the FIGO staging
system and patient prognosis. Moreover, biomarkers such as
CA125, CA199, and CA153 have been used for predicting me-
tastasis and prognosis in the clinic [5].Many novel genes, such as
AGR2, Netrin-1 and STIP1, have been reported to be potentially
useful metastatic and prognostic markers in ovarian cancer [6–8].
However, they are not sufficiently reliable for predicting tumor
metastasis, clinical outcomes or for optimizing and individualiz-
ing the treatment. Thus, an urgent need remains for additional
research to identify novel biomarkers for developing targeted
therapy, detection of metastasis, and predicting the survival and
relapse rates for ovarian cancer patients.
Centrosomal protein 55 (CEP55), also designated as
C10orf3, FLJ10540, or URCC6, is a centrosome- and
midbody-associated protein of ~55 kDa in size and has been
mapped to the 10q23 chromosomal region [9]. The CEP55
gene encodes the 464 amino acid protein containing a domain
known as AAA (ATPases associated with a variety of cellular
activities). CEP55 was found to play a role in centrosome-
dependent cellular functions, such as centrosome duplication
and/or cell cycle progression, or in the regulation of cytokinesis
[10–13]. Recently, increased expression of CEP55was reported
in several human tumors, and it may be associated with the
onset of oncogenesis, invasion, and mitosis. A study indicated
that CEP55 forms a complex with PI3K, enhancing PI3K ac-
tivity, and consequently, the AKTsurvival pathway, suggesting
that CEP55 is a novel oncogene that may play an important role
in hepatocarcinogenesis [14]. A higher level of CEP55 has been
associated with poor prognosis in ER+ breast cancer patients
[15]. It is reported that the early upregulation of FOXM1 during
head and neck cancer progression, rendering it as an attractive
diagnostic biomarker for early cancer detection and its candi-
date mechanistic targets, CEP55 and HELLS, as indicators of
malignant conversion and progression [16]. In addition, expres-
sion of CEP55was correlatedwith aggressiveness of oral cavity
squamous cell carcinoma by stimulating cell migration and
invasion through increased FOXM1 and MMP-2 activity
[17]. CEP55 was reported to be overexpressed in lung cancer
tissues and associated with cell migration and invasion, as well
as participate in the VEGF-A/PI3K/AKT pathway [18, 19].
Furthermore, some studies have identified the overexpression
of CEP55 in colorectal carcinoma, prostate cancer, nasopharyn-
geal carcinoma, and gastric cancer [20–26]. However, charac-
teristics of CEP55 expression and its clinical/prognostic signif-
icance in human ovarian cancer remain unknown.
In the current study, we aimed to explore the expression of
CEP55 in ovarian cell lines and human ovarian tissues.
Moreover, we investigated the association between the ex-
pression of CEP55 protein and clinical manifestations and
survival outcomes of a cohort of 213 patients with ovarian
cancer. We further investigated the function of CEP55 by
using RNA interference (RNAi), wound healing assay,
Transwell assay, immunofluorescence analysis, quantitative
real-time PCR (qRT-PCR), and Western blot analysis, .
Methods
Samples and patients
This study was approved by the Sun Yat-sen University Cancer
Center Ethic Review Committee, and each patient signed an
informed consent prior to the use of the clinical materials for
research purposes. All specimens were handled according to
the ethical and legal standards. For qRT-PCR and Western blot
analysis, fresh ovarian cancer and matched distant noncancer-
ous ovarian tissues were derived from 12 patients who had
undergone surgery at the Sun Yat-sen University Cancer
Center between March 2015 and May 2015. For Western blot
analysis of different stages of ovarian cancer, we collected nor-
mal ovarian tissue, benign ovarian cancer tissue, and borderline
ovarian cancer and ovarian cancer tissues from patients at dif-
ferent clinical stages from seven patients who had undergone
surgery at the Sun Yat-sen University Cancer Center between
January 2015 and June 2015. In addition, immunohistochemi-
cal (IHC) analysis was conducted on a total of 213 paraffin-
embedded ovarian cancer samples, which were histopatholog-
ically and clinically diagnosed at the Sun Yat-sen University
Cancer Center between 2002 and 2010. Clinical and clinico-
pathological classification and staging were determined by two
experienced gynecological oncologists according to FIGO
(2009). The follow-up time for the primary ovarian cancer co-
hort ranged from 5.1 to 176.1 months with a median of
73.82 months. The clinicopathological data of all the patients
were summarized in Table 1.
Cell lines
The ovarian cancer cell lines used in the current study were
obtained from American Type Culture Collection (ATCC,
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Manassas, VA). TOV-112D, COV434, OV-90, COV644,
COV504, COV362, A2780, TOV-21G, SKOV3, OVCAR4,
and EFO-27 were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco, Grand Island, NY, USA) supple-
mented with 10 % fetal bovine serum (FBS, HyClone, Logan,
UT, USA) and 1 % antibiotics (100 U/ml penicillin and
100 ug/ml streptomycin). The normal ovarian cell line
HOSEpiC was maintained in DMEM.
qRT-PCR analysis
qRT-PCR was performed to detect the expression levels of
CEP55 in ovarian cell lines, human epithelial ovarian cancer,
and matched adjacent normal tissues. Total RNA samples
from cultured cells and fresh tissues were isolated using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. These RNA samples were
then pretreated with RNase-free DNase, and 2 μg of RNA
sample was used for cDNA synthesis using random hexamers.
The primers were designed using Primer Express v2.0
(Applied Biosystems, USA). CEP55 primers used were 5′-
GCCACTGCTGATTTTTCTCC-3′, and 5′-ACTGTGGC
TCCAAACTGCTT-3′.
Table 1 Clinicopathological characteristics and tumor expression of
CEP55 in patients with EOC










Serous adenocarcinoma 154 (72.3)
Mucoid adenocarcinoma 44 (20.7)
Endometrial adenocarcinoma 9 (4.2)

















G1/G2 128 (60. 1)
G3 85 (39.9)
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For the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene, which was used as an internal control, the
sense primer 5′-AATGAAGGGGTCATTGATGG-3′ and the
antisense primer 5′-AAGGTGAAGGTCGGAGTCAA-3′
were used. For PCR-mediated amplification of CEP55
cDNA, an initial amplification step using CEP55-specific
primers was conducted with a denaturation step at 95 °C for
10 min, followed by 30 denaturation cycles at 95 °C for 60 s,
primer annealing at 55 °C for 30 s, and a primer extension
phase at 72 °C for 30 s. Upon the completion of the cycling
steps, a final extension at 95 °C was carried out before the
reaction mixture was held at 4 °C. qRT-PCR was then per-
formed to evaluate the fold increase of CEP55mRNA in each
of the primary ovarian cancer tissues relative to the matched
adjacent normal tissues (ANT) and ovarian cancer cell lines
relative to that in the normal ovarian cell line. We used a
double-stranded DNA-specific SYBR Premix Ex Taq II kit
(Takara Biotechnology, USA) on a Bio-Rad sequence evalu-
ation system according to the manufacturer’s instructions. The
expression data were normalized to the geometric mean of the
level for GAPDH to control for variability in expression levels
in all experiments. All assays were examined in triplicate.
Western blotting
Total protein was prepared using the cell total protein extrac-
tion kits according to the manufacturer’s instruction
(Millipore, Billerica, MA). Equal concentrations of each pro-
tein sample (20 μg) were separated on 6 % SDS polyacryl-
amide gels and transferred to polyvinylidene fluoride (PVDF)
membranes (Immobilon P, Millipore, Bedford, MA, USA).
The membranes were blocked with 5 % nonfat milk in Tris-
buffered saline containing 0.1 % Tween 20 (TBST) for 1 h at
room temperature, and incubated a primary monoclonal anti-
body to CEP55 (1:1000, Abcam, USA, ab170414) overnight
at 4 °C. After washing with TBST, the membranes were incu-
bated with horseradish peroxidase-conjugated goat anti-rabbit
IgG (Santa Cruz Biotechnology, Dallas, TX, USA, SC-2004).
The ECL prime Western blotting detection reagent
(Amersham Pharmacia Biotech, Piscataway, NJ) was used to
detect CEP55 expression according to the manufacturer’s in-
structions. GADPH (Santa Cruz Biotechnology) was used to
confirm equal loading of the samples.
IHC analysis
IHC analysis was carried out to investigate alterations in pro-
tein expression in the 213 human ovarian cancer tissues. The
procedures were performed with classical protocols. In brief,
paraffin-embedded specimens were cut into 4-μm sections and
baked at 65 °C for 30 min. The sections were deparaffinized
with xylene and rehydrated. Sections were submerged into
EDTA antigenic retrieval buffer, microwaved for antigenic
retrieval, and then treated with 3 % hydrogen peroxide in meth-
anol to quench endogenous peroxidase activity, followed by
incubation with 1 % bovine serum albumin (BSA) to block
any nonspecific binding. Sections were then incubated with a
rabbit monoclonal antibody against CEP55 (Abcam, ab170414,
1:250) overnight at 4 °C. After washing, the tissue sections
were then incubated with a biotinylated anti-rabbit secondary
antibody (Abcam), followed by further incubation with a
streptavidin-horseradish peroxidase complex (Abcam). The tis-
sue sections were immersed in 3-amino-9-ethyl carbazole and
counterstained with 10 % Mayer’s hematoxylin, dehydrated
and mounted in Crystal Mount.
The degree of immunostaining of formalin-fixed, paraffin-
embedded sections was blind reviewed and evaluated by two
independent pathologists. Scores given by the two indepen-
dent observers were averaged, which were based on both the
proportion of positively stained tumor cells and the intensity
of staining. The proportion of tumor cells was scored as fol-
lows: 1 (<10 % positive tumor cells), 2 (10–50 % positive
tumor cells), 3 (50–75 % positive tumor cells), and 4
(>75 % positive tumor cells). Cells were scored for intensity
of staining on a scale of 0 (no staining), 1 (weak staining=
light yellow), 2 (moderate staining=yellow brown), and 3
(strong staining=brown). The staining index was calculated
as the product of the proportion of positive cells×stain-
ing intensity score (range from 0 to 12). Cutoff values
for CEP55 were chosen on the basis of a measure of
heterogeneity using the log-rank test with respect to
overall survival (OS). An optimal cutoff value was iden-
tified as follows: staining index score of ≥6 was used to
define tumors with high CEP55 expression, and a score
of ≤4 indicated low CEP55 expression.
RNAi and transfection
To further identify the role of CEP55 in tumor invasion, two
human small interfering RNAs (siRNAs) were synthesized
and purified by Ribobio Inc (Guangzhou, Guangdong,
China) for depletion of CEP55. The siRNA sequences used
were as follows: siRNA#1: 5′-GAAGCCUAGUAACUCC
AAAdTdT-3 ′ , siRNA#2: 5 ′-GGAAGAUGAUAGG
CAUAAAdTdT-3′, and siRNA#3: 5′-GGAAACAGCUG
CUCAUUCAdTdT-3′. Transfection of siRNAs was carried
out using Lipofectamine 2000 reagent (Invitrogen) according
to the instructions of the manufacturer.
Cell invasion assay
In the cell invasion assay, we used Transwell chambers
(Costar, Cambridge, MA, USA) with 8-μm pore polycarbon-
ate filters that were coated with Matrigel™ (BD Biosciences,
Franklin Lakes, NJ, USA). Cells cultured in the absence or
presence of siRNA for 24 h were seeded into the upper
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chambers in serum-free medium at a density of 2.5×104 per
well, and 500 μl of NIH3T3-conditioned medium was placed
in the lower chamber as a chemoattractant. After 48 h at 37 °C
in 5 % CO2, the cells that passed through the filter into the
lower chamber were fixed with 3.7 % paraformaldehyde and
stained with 0.1 % crystal violet solution. Cells on the
upper surface of the filter were removed with cotton
buds. Invaded cells on the underside of the filter were
photographed and counted by phase contrast microscopy
(×200 magnification). The experiments were performed
in triplicate.
Wound-healing assay
For wound-healing assay, cells were seeded in individual
wells of a six-well culture plate. Untransfected cells and cells
exposed to CEP55 siRNA or negative control siRNA for 5 h
were cultured in a quiescent medium for 24 h.
Thereafter, a sterile 10-μl pipette tip was used to longi-
tudinally scratch a constant-diameter stripe in the con-
fluent monolayer. The medium and cell debris were re-
moved by aspiration and replaced with 2 ml of fresh
serum-free medium. Microscopic images were taken at
0, 24, and 48 h immediately after wounding (corre-
sponding to 24, 48, and 72 h posttransfection) by phase
contrast microscopy. For statistical analysis, three ran-
domly selected points along each wound were marked,
and the horizontal distance between the migrating cells
and the initial wound was measured at 24 and 48 h.
Values were means±standard deviation (SD) from at
least three independent experiments. Differences be-
tween siRNA-treated and blank control data were deter-
mined by a Student’s t test, where P<0.05 was consid-
ered significant.
Immunofluorescence analysis
After a 5-h exposure to CEP55 siRNA, negative control
siRNA, or no treatment, SKOV3 and TOV-21G cells were
cultured overnight on sterile glass coverslips in a six-well
plate for 24 h. The cells were washed in PBS, fixed in 3.7 %
paraformaldehyde, permeabilized in 0.1 % Triton-X100, and
incubated in blocking solution (1%BSA). The cells were then
incubated with primary antibodies against E-cadherin, N-
cadherin, β-catenin, or fibronectin (BD Transduction
Laboratories, Lexington, UK) and then incubated with
rhodamine-conjugated goat antibodies against rabbit or mouse
IgG (Jackson ImmunoResearch Laboratories, USA). The cov-
erslips were counterstained with DAPI (Sigma-Aldrich, St
Louis, MO) and imaged with a confocal laser-scanning micro-
scope (Olympus FV1000, Japan). Data were processed with
Adobe Photoshop 7.0.
Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software packages. The associations of
clinicopathological characteristics with the expression
status of CEP55 were assessed using the chi-square test
and Fisher’s exact test. Bivariate correlations between
studied variables were calculated by Spearman’s rank
correlation coefficients. Survival curves were plotted by
theKaplan–Meiermethod, and differences were analyzed using
the log-rank test. Multivariate analysis was performed using the
Cox proportional hazards regression model on all significant
characteristics determined using univariate analysis. All P
values were two-sided. A P value of <0.05 was considered to
be statistically significant in all cases.
Results
CEP55 is upregulated in ovarian cancer
Western blot and qRT-PCR analyses revealed high levels of
CEP55 expression in all 11 ovarian cell lines tested compared
with the immortalized normal ovarian epithelial cell line
HOSEpiC (Fig. 1a, b). In order to determine whether the
Fig. 1 Overexpression of CEP55 mRNA and protein in ovarian cancer
cell lines. a, b Expression of CEP55 mRNA and protein in ovarian cancer
cell lines (TOV-112D, COV434, OV-90, COV644, COV504, COV362,
A2780 and TOV-21G, SKOV3, OVCAR4, EFO-27) and the normal
ovarian cell line HOSEpiC (N) were examined by Western blotting (a)
and qRT-PCR (b). Expression levels were normalized against GAPDH.
Results are shown as the fold increase in CEP55 mRNA expression
relative to that of normal ovarian cells. Error bars represent the SD of
the mean calculated from three parallel experiments (*P<0.05)
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CEP55 upregulation found in ovarian cancer cell lines was
related to clinical biochemical indicators, we didWestern blot-
ting analysis on 12 paired epithelial ovarian carcinoma tissues
and noncancerous tissues adjacent to ovarian tumors. As
shown in Fig. 2a, b, CEP55 protein expression was higher in
all 12 epithelial ovarian carcinoma samples, displaying more
than a threefold increase compared with that in the adjacent
noncancer tissue samples. These findings above are consistent
with the results obtained in our immunohistochemical analysis
(Fig. 2c). Moreover, CEP55 was shown to be predominantly
located in the cytoplasm of tumor cells (Figs. 2c and 3c). As
shown in Fig. 3a, Western blotting results indicated that CEP55
protein expression was low in normal ovarian tissue, benign
ovarian cancer tissue, and borderline ovarian cancer tissue,
while it was high in ovarian carcinoma tissues from
patients at different clinical stages. Interestingly,
Western blot analysis showed that CEP55 protein ex-
pression levels were positively correlated with clinical
stages of ovarian carcinoma patients.
CEP55 overexpression is associated with clinical features
of ovarian cancer
To further determine whether CEP55 protein overexpression
is associated with clinicopathological characteristics of epithe-
lial ovarian cancer, 213 paraffin-embedded, archived ovarian
cancer tissue samples were examined by immunohistochemi-
cal analysis. The samples included 59 cases at stage I, 36 cases
at stage II, 100 cases at stage III, and 18 cases at stage IV. In
the cohort, CEP55 expression in 213 enrolled patient samples
was determined as strong in 99 cases (46.5 %) and weakly
positive or negative in 114 cases (53.5 %) (Table 1). As shown
in Fig. 4, the immunoreactivity of CEP55 was detected at
variable levels, and specific CEP55 staining was mostly found
in the cytoplasm of carcinoma cells. Additionally, the CEP55
protein expression was generally weak in early stage ovarian
cancer (FIGO stages I and II), while it was strong in later stage
ovarian cancer (FIGO stages III and IV) tissues (Fig. 3c).
Quantitative analysis indicated that the mean optical density
Fig. 2 Overexpression of CEP55
mRNA and protein in EOC
tissues. a Representative images
of Western blotting analyses of
CEP55 protein expression in 12
matched pairs of ovarian cancer
(T) and adjacent noncancerous
tissues. The expression level was
normalized by GADPH
expression. b Average T/N ratios
of CEP55 mRNA expression in
paired ovarian cancer (T) and
adjacent noncancerous tissues (N)
were quantified by qRT-PCR and
normalized against GAPDH.
Results are shown as the fold
increase in CEP55 mRNA
expression relative to that of
adjacent noncancerous tissues
(N). Error bars represent the SD
of the mean calculated from three
parallel experiments. c
Immunohistochemical assay of
CEP55 protein expression in 12
pairs of matched ovarian cancer
tissues (*P<0.05)
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(MOD) values of CEP55 staining in clinical stage I–IV pri-
mary tumors were statistically significantly higher than those
in the normal control ovarian tissues. In addition, the MOD
values of CEP55 staining significantly increased with
progression from stage I to IV (P<0.001, Fig. 3b).
Taken together, these observations suggested that aber-
rant CEP55 expression was associated with the clinical
development of primary ovarian tumors.
Statistical analyses were employed to detect the correlation
between CEP55 expression and the clinicopathological char-
acteristics of ovarian cancer patients (Table 1). As summa-
rized in Table 2, no significant correlations were detected be-
tween the expression level of CEP55 protein and patient age,
histological type, and serum CA125, CA199, NSE, CEA, β-
HCG, or CA724 expression levels in patients with ovarian
cancer. However, CEP55 expression was markedly associated
with clinical stage (P<0.001), lymph node metastasis
(P<0.001), intraperitoneal metastasis (P<0.001), tumor recur-
rence (P<0.001), differentiation grade (P<0.001), residual
tumor size (P<0.001), ascites see tumor cells (P=0.020),
and serum CA153 level (P<0.001) in patients with ovarian
cancer. Moreover, patients with aberrant CEP55 protein ex-
pression showed tendencies to receive neoadjuvant chemo-
therapy (P<0.001) and cytoreductive surgery (P=0.020).
These data were further confirmed by association coefficient
analyses assessing the correlation between CEP55 expression
and clinicopathological features. As shown in Table 3, corre-
lations between CEP55 expression and clinical stage, lymph
Fig. 3 The expression of CEP55
in epithelial ovarian cancer tissues
from patients at different clinical
stages. a Representative images
of Western blotting analyses of
CEP55 protein expression in
normal ovarian tissue, benign
ovarian cancer tissue, and
borderline ovarian cancer and
ovarian cancer tissues from
patients at different clinical
stages. b Statistical analyses of
the average MOD of CEP55
staining in normal ovarian tissue
and ovarian cancer specimens at
different clinical stages. Values
represent the mean±SD from
three independent experiments.
Results are shown as the fold
increase in MOD of CEP55
staining relative to that of normal
ovarian tissue (*P<0.05). c
Representative images from
immunohistochemical analyses of
CEP55 expression in ovarian
cancer tissues at different clinical
stages
Fig. 4 Representative images from immunohistochemical analyses of
CEP55 expression in different histotypes of EOC specimens. a, b High
expression in serous histotypes. c, d High expression in mucinous
histotypes. e, f High expression in endometrioid histotypes. g, h High
expression in clear cell histotypes
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node metastasis, intraperitoneal metastasis, tumor recurrence,
differentiation grade, residual tumor size, serum CA153 level,
and ascites see tumor cells were 0.550 (P<0.001), 0.328
(P<0.001), 0.414 (P<0.001), 0.607 (P<0.001), 0.251
(P<0.001), 0.235 (P<0.001), 0.289 (P<0.001), and 0.157
(P=0.020), respectively.
Table 2 Correlation between CEP55 expression and clinicopathologic features of EOC








Age (years) <53 111 59 (27.7) 52 (24.4) 0.911 1.000
≥53 102 55 (25.8) 47 (22.1)
FIGO stage I 59 56 (26.3) 3 (1.4) <0.001 –
II 36 29 (13.6) 7 (3.3)
III 100 27 (12.7) 73 (34.3)
IV 18 2 (0.9) 16 (7.5)
Lymph node metastasis Absent 173 107 (50.2) 66 (31.0) <0.001 <0.001
Present 40 7 (3.3) 33 (15.5)
Histological type Serous cell carcinoma 154 82 (38.5) 72 (33.8) 0.143 –
Mucous cell carcinoma 44 20 (9.4) 24 (11.3)
Endometrial carcinoma 9 7 (3.3) 2 (0.9)
Clear cell carcinoma 6 5 (2.3) 1 (0.5)
Intraperitoneal metastasis No 110 83 (39.0) 27 (12.7) <0.001 <0.001
Yes 103 31 (14.5) 72 (33.8)
Tumor recurrence No 121 105 (49.3) 16 (7.5) <0.001 <0.001
Yes 92 9 (4.2) 83 (39.0)
Vital status (at last follow-up) No 111 95 (44.6) 16 (7.5) <0.001 <0.001
Yes 102 19 (8.9) 83 (39.0)
Differentiation grade G1/G2 128 82 (38.5) 46 (21.6) <0.001 <0.001
G3 85 32 (15.0) 53 (24.9)
Residual tumor ≤1 150 92 (43.2) 58 (27.2) <0.001 0.001
Size (cm) >1 63 22 (10.3) 41 (19.3)
Neoadjuvant chemotherapy No 158 96 (45.1) 62 (29.1) <0.001 <0.001
Yes 55 18 (8.4) 37 (17.4)
Postoperative chemotherapy No 22 11 (5.2) 11 (5.2) 0.727 0.823
Yes 191 103 (48.3) 88 (41.3)
HIPEC No 142 78 (36.6) 64 (30.1) 0.560 0.564
Yes 71 36 (16.9) 35 (16.4)
Ascites see tumor cells (+) No 148 87 (40.8) 61 (28.6) 0.020 0.025
Yes 65 27 (12.7) 38 (17.8)
Cytoreductive surgery No 71 46 (21.6) 24 (11.3) 0.020 0.021
Yes 142 68 (31.9) 74 (34.7)
CA125 (U/ml) ≤35 14 10 (4.7) 4 (1.9) 0.165 0.267
>35 197 103 (48.8) 94 (44.6)
CA199 (U/ml) ≤35 156 83 (39.3) 73 (34.6) 0.686 0.754
>35 55 31 (14.7) 24 (11.4)
CA153 (U/ml) ≤25 82 59 (29.1) 23 (11.3) <0.001 <0.001
>25 121 50 (24.6) 71 (35.0)
NSE (U/ml) ≤15.2 46 27 (18.5) 19 (13.0) 0.387 0.475
>15.2 100 51 (34.9) 49 (33.6)
CEA (U/ml) ≤5.0 67 41 (51.3) 26 (32.5) 0.621 0.759
>5.0 13 7 (8.7) 6 (7.5)
β-HCG (U/ml) ≤3.0 65 35 (38.5) 30 (33.0) 0.315 0.356
>3.0 26 17 (18.7) 9 (9.9)
CA724 (U/ml) ≤5.3 5 1 (7.7) 4 (30.8) 0.506 1.000
>5.3 8 3 (23.1) 5 (38.5)
HIPEC hyperthermic intraperitoneal chemotherapy, FIGO International Federation of Gynecology and Obstetrics
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Survival analysis
To identify factors with potential prognostic significance in
ovarian patients, univariate analysis for each variable was per-
formed in relation to the survival time. In our univariate anal-
ysis, stepwise inclusion of variables in the model indicated
that significant prognostic factors included CEP55 protein
level, lymph node metastasis, intraperitoneal metastasis,
FIGO stage, differentiation grade, recurrence, age, CA153
serum level, and neoadjuvant chemotherapy. In addition,
multivariate Cox regression analysis revealed that
CEP55 protein level, lymph node metastasis, intraperi-
toneal metastasis, FIGO stage, recurrence, age, and neo-
adjuvant chemotherapy were indeed independent prog-
nostic markers for ovarian cancer (Table 4).
To further determine the value of CEP55 expression in
predicting survival of ovarian cancer patients, Kaplan–Meier
analysis and the log-rank test were used in this study. The log-
rank test showed that the survival time was significantly dif-
ferent between these two groups. As shown in Fig. 5, CEP55
expression in ovarian cancer patients was associated with sur-
vival time, with the patients expressing low CEP55 in their
ovarian cancer lesions surviving much longer than those with
high CEP55 expression (P<0.001). The cumulative OS and
disease-free survival (DFS) rates for the patients with high
levels of CEP55 expression were 38.9 and 43.6 %, respective-
ly, whereas these rates were 84.5 and 91.6 %, respectively, for
patients with low or no CEP55 expression. Moreover, we
analyzed the prognostic value of CEP55 expression in select-
ed patient subgroups stratified according to characteristics of
residual tumor size, serum CA125 level, serum CA153 level,
serum CA199 level, differentiation, FIGO stage, intraperito-
neal metastasis, and ascites see tumor size, as well as
treatments of hyperthermic intraperitoneal chemotherapy
(HIPEC), neoadjuvant chemotherapy, cytoreductive surgery,
and postoperative chemotherapy. Patients with tumors
exhibiting high CEP55 expression had a significantly shorter
OS compared to those with low CEP55-expressing tumors in
the residual tumor size ≤1 cm subgroup (log-rank test,
P<0.001, Fig. 6a), residual tumor size >1 cm subgroup (log-
rank test, P<0.001, Fig. 6b), CA125 >35 U/ml subgroup (log-
rank test, P<0.001, Fig. 6c), CA153 >25 U/ml subgroup (log-
rank test, P<0.001, Fig. 6d), CA199 >35 U/ml subgroup (log-
rank test, P<0.001, Fig. 6e), in those receiving HIPEC (log-
rank test, P<0.001, Fig. 6f), in the differentiation grade 1 and
2 subgroup (log-rank test, P<0.001, Fig. 6g), in the differen-
tiation grade 3 subgroup (log-rank test, P<0.001, Fig. 6h), in
those with ascites see tumor cells (log-rank test, P<0.001,
Fig. 6i), in the stage 1 and 2 subgroups (log-rank test,
P<0.001, Fig. 6j), in the stage 3 and 4 subgroups (log-rank
test, P<0.001, Fig. 6k), in those with intraperitoneal metasta-
sis (log-rank test, P<0.001, Fig. 6l), in those receiving neoad-
juvant chemotherapy (log-rank test, P<0.001, Fig. 6m), in
those receiving cytoreductive surgery (log-rank test,
P<0.001, Fig. 6n), and in those receiving postoperative che-
motherapy (log-rank test, P<0.001, Fig. 6o).
Specific silencing of CEP55 in SKOV3 and TOV-21G cells
with CEP55 siRNA
To further investigate the role of CEP55 in the invasion of
ovarian cancer, we transfected SKOV3 and TOV-21G cells
with 200 pmol siRNA for 24 h, which offered the best silenc-
ing efficiency in our preliminary experiments. Three different
siRNA duplexes targeting CEP55 and a negative control
siRNA were separately transferred into SKOV3 and TOV-
21G cells. At 24 h after transfection, we examined the
resulting phenotype using Western blot analysis. As shown
in Fig. 7, CEP55 siRNA1 and CEP55 siRNA3 duplexes ob-
viously reduced CEP55 protein in both ovarian cancer cell
lines, and these more efficient siRNAs were therefore chosen
for subsequent studies. The data were obtained from densito-
metric analyses of the ratio of CEP55 to β-actin protein levels
(n=5 independent experiments).
Silencing of CEP55 inhibits migration and invasion
in SKOV3 and TOV-21G cells
Cancer cell migration and invasion are directly related to me-
tastasis, and CEP55 has been reported to be related to the
processes of cell mobility and cancer metastasis [20]. In order
to determine whether CEP55 induces epithelial–mesenchymal
transition (EMT), we probed the cancer cell lines with epithe-
lial and mesenchymal markers. As shown in Fig. 7, SKOV3
and TOV21G cells showed high CEP55 levels and the typical
EMT phenotype, including downregulation of epithelial
Table 3 Correlation between CEP55 expression and clinicopathological
characteristics of patients with EOC
Variable CEP55 expression
Association coefficient P value
FIGO Stage 0.550 <0.001
Lymph node metastasis 0.328 <0.001
Intraperitoneal metastasis 0.414 <0.001
Tumor recurrence 0.607 <0.001
Vital status (at last follow-up) 0.557 <0.001
Differentiation grade 0.251 <0.001
Residual tumor size (cm) 0.235 <0.001
Neoadjuvant chemotherapy 0.239 <0.001
Cytoreductive surgery 0.158 0.020
Ascites see tumor cells (+) 0.157 0.020
CA153 (U/ml) 0.289 <0.001
FIGO International Federation of Gynecology and Obstetrics, EOC epi-
thelial ovarian carcinoma
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markers E-cadherin and β-catenin and upregulation of mes-
enchymal markers fibronectin and N-cadherin. As shown in
Fig. 7a, c, silencing endogenous CEP55 in SKOV3 and
TOV21G cells led to enhanced expression of epithelial
markers and concomitant decreased expression of mesenchy-
mal markers. The EMT phenotype was confirmed by immu-
nofluorescent staining in SKOV3 and TOV-21G cells
(Fig. 7b, d).
To further determine whether repression of CEP55 expres-
sion would inhibit SKOV3 and TOV-21G cell migration and
invasion, a wound-healing assay and a cell invasion assay
were performed on these two cell lines either untransfected
or transfected with CEP55 siRNA1, CEP55 siRNA3, or neg-
ative control siRNA for 24 h. Results of the wound-healing
assay revealed that the invasiveness of SKOV3 and TOV21G
cells was dramatically hampered by the ablation of CEP55
(Fig. 8b). As shown in Fig. 8a, the number of SKOV3 cells
that passed through the filter in the CEP55 siRNA1- and
siRNA3-treated groups was remarkably lower than that in
the untreated or negative control treated siRNA groups, indi-
cating that inhibition of CEP55 expression suppressed
SKOV3 and TOV-21G cell invasion in vitro.
Discussion
To our knowledge, this study is the first to show that highly
expressed CEP55 in patients with epithelial ovarian carcino-
ma was significantly correlated with clinical stage, lymph
node metastasis, intraperitoneal metastasis, tumor recurrence,
differentiation grade, residual tumor size, ascites see tumor
cells, and serum CA153 level. Moreover, patients with aber-
rant CEP55 protein expression showed a tendency to receive
neoadjuvant chemotherapy and cytoreductive surgery. The
loss of CEP55 function mediated by RNAi in ovarian cancer
cell models indicated that suppression of CEP55 repressed
Table 4 Univariate and multivariate analyses of prognostic factors in EOC using a Cox-regression model
Univariate analysis Multivariate analysis
No. patients P Regression coefficient (SE) P Relative risk 95 % confidence interval
Lymph node metastasis
Absent 173 <0.001 4.297 (0.215) <0.001 2.262 1.429–3.581
Present 40
FIGO stage





Low expression 114 <0.001 11.729 (0.264) 0.015 2.705 1.209–6.054
High expression 99
Recurrence
No 121 <0.001 9.132 (0.242) 0.003 4.419 1.659–11.768
Yes 92
Age (years)
<53 111 0.036 1.520 (0.199) <0.001 2.574 1.662–3.985
≥53 102
Differentiation
G1/G2 128 0.005 1.746 (0.199) 0.822 0.953 0.624–1.455
G3 85
Intraperitoneal metastasis
No 110 <0.001 4.415 (0.223) 0.003 2.023 1.262–3.243
Yes 103
CA153 (U/ml)
<38 82 <0.001 2.376 (0.231) 0.368 0.793 0.479–1.314
>38 121
Neoadjuvant chemotherapy
No 158 0.036 1.561 (0.212) 0.011 0.555 0.352–0.873
Yes 55
EOC epithelial ovarian carcinoma, FIGO International Federation of Gynecology and Obstetrics
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cellular invasion, demonstrating the involvement of CEP55 in
enhancing the migratory and invasive activity in ovarian can-
cer cells. Furthermore, elevated expression levels of CEP55
protein served as independent prognostic factors for short OS
and DFS rate in patients with EOC. In light of these findings,
our results suggest that overexpression of CEP55 pro-
tein is associated with tumor aggressiveness and may
represent an independent prognostic factor for clinical
outcomes in EOC patients.
Recent studies have indicated overexpression of CEP55 as
an important event in patients with certain types of cancer. Its
elevated expression has been shown to be associated with
carcinogenesis in bladder cancer, breast cancer, gastric cancer,
and colon cancer [21–26]. Moreover, high CEP55 expression
was found to promote progrowth signaling pathways resulting
in cancer cell metastasis and poor patient prognosis [14, 23].
Altogether, these findings suggest that CEP55 may play an
oncogenic role in cancer development and progression. In
our cohort, we examined the expression of CEP55 mRNA
and protein in ovarian cancer cell lines and ovarian cancer
samples. We found that both CEP55 mRNA and protein
showed aberrant expression levels in ovarian cancer tissues
compared with noncancerous tissues, indicating that the over-
expression of CEP55 occurred not only at the posttranscrip-
tional level but also at the transcriptional level. Furthermore,
we analyzed the correlation between CEP55 expression and
the clinicopathological features of ovarian cancer patients. We
found that CEP55 protein expression was significantly corre-
lated with FIGO stage, tumor recurrence, differentiation
grade, residual tumor size, ascites see tumor cells, serum
CA153 level, lymph node metastasis, and intraperitoneal me-
tastasis strongly supporting the hypothesis that this protein
plays a role in the progression of ovarian cancer. Patients with
CEP55 protein overexpression showed a tendency to accept
neoadjuvant chemotherapy and cytoreductive surgery. In ad-
dition, univariate and multivariate analyses showed high
CEP55 protein expression as a predictor of poor prognosis
in these patients. Patients with elevated CEP55 expression
showed a 38.9 % cumulative OS rate, which was significantly
lower than that in patients with low expression levels of this
protein (91.6 %). Taken together, these findings provide with
essential, reliable evidence for the clinical significance of
CEP55 as an independent prognostic marker to identify ovar-
ian cancer patients with poor prognosis. Using CEP55 bio-
marker to identify patients with a higher risk of developing
worse clinical outcome may thus help patients choose better
treatment and reduce mortality.
To date, lymph node metastasis and intraperitoneal metas-
tasis play important roles in determining the ovarian carcino-
ma staging. According to FIGO (2013), stage III is divided
into three substages: stage IIIA, stage IIIB, and stage IIIC.
Moreover, stage IIIA is divided further into substages IIIA1
and IIIA2. Ovarian cancer patients only with a positive retro-
peritoneal lymph node are classified as stage IIIA1, while
patients with microscopic intraperitoneal metastasis are de-
fined as stage IIIA2. Furthermore, patients who have macro-
scopic intraperitoneal metastasis are determined as stage IIIB
and IIIC. In addition, recent studies reported that lymph node
metastasis represents poor clinical prognosis for ovarian can-
cer patients [27]. Early diagnosis of intraperitoneal metastasis
is pivotal for the survival of patients with EOC [28].
Therefore, having the ability to predict lymph node metastasis
and intraperitoneal metastasis is critically important, but no
ideal, preoperative marker has been established. In our study,
we found that aberrant CEP55 protein expression was signif-
icantly associated with lymph node metastasis and intraperi-
toneal metastasis. Moreover, we observed a significant corre-
lation between shorter OS and high CEP55 protein expression
in the subgroup with intraperitoneal metastasis, which indi-
cates that CEP55 may be a useful prognostic marker for such
ovarian cancer patients. EMT has been found to contribute to
invasion, metastatic dissemination, and acquisition of thera-
peutic resistance of cancer cells [29]. Several reports have
Fig. 5 Survival curves of patients with EOC, subdivided according to
CEP55 protein expression (log-rank test). a, bOS (a) and 5-year DFS (b)
rates for cases with high CEP55 expression versus those for cases with
low CEP55 expression levels in all patients
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shown that CEP55 plays an important role in regulating EMT.
For example, increased CEP55 expression was reported to
promote EMT in nasopharyngeal carcinoma via the
osteopontin/CD44 pathway [23, 24]. Chen et al. [17] showed
that CEP55 could regulate EMT through the CEP55/FOXM1/
MMP-2 pathway in oral cavity squamous cell carcinoma.
Moreover, overexpression of CEP55 was shown to regulate
EMT through the VEGF-A/PI3K/AKT pathway in lung can-
cer [18]. Here, we suppressed CEP55 expression by siRNA
and demonstrated, for the first time, that downregulation of
CEP55 remarkably repressed ovarian cancer cellular invasion
and reversed EMT. However, further studies are required to
obtain a detailed picture of CEP55-related signaling pathways
in regulating ovarian cancer EMT.
Although primary cytoreductive surgery followed by che-
motherapy has been the standard treatment for advanced ovar-
ian cancer for many years, neoadjuvant chemotherapy follow-
ed by interval debulking surgery has emerged as a new alter-
native treatment. National Comprehensive Cancer Network
(NCCN) guidelines indicate that patients with a clear diagno-
sis of histopathology, patients with ascites cytology showing
malignant tumor cells, as well as those with a physical exam-
ination and imaging examination or exploratory laparotomy
determining that the tumor would be difficult to remove
should accept neoadjuvant chemotherapy [30]. Recent studies
have shown the benefit of neoadjuvant chemotherapy for ad-
vanced ovarian cancer patients. Kang et al. [31] found that
neoadjuvant chemotherapy was not only equally effective
but also a substantially safer strategy compared with standard
treatment. Neoadjuvant chemotherapy, followed by surgical
cytoreduction, is reportedly a promising treatment strategy
for the management of advanced EOC [32]. Interestingly,
Fig. 6 Kaplan–Meier curves of univariate analysis data (log-rank test) in
select patient subgroups. Shown are OS rates for patients with high versus
low CEP55 expression who had a residual tumor size ≤1 cm, b residual
tumor size >1 cm, c CA125 >35 U/ml, d CA153 >25 U/ml, e CA199>
35 U/ml, f received HIPEC, g differentiation grade 1–2, h differentiation
grade 3, i ascites see tumor cells, j FIGO stages I-II, k FIGO stages III–IV, l
intraperitoneal metastasis, m received neoadjuvant chemotherapy, n
received cytoreductive surgery, and o received postoperative chemotherapy
Fig. 7 Downregulation of
CEP55 reversed EMT. a, c
Expression levels of CEP55 and
EMT markers were analyzed by
Western blotting. β-actin was
used as the loading control. b, d
Immunofluorescence assay of
EMT markers (×200)
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ovarian cancer patients in our study with aberrant CEP55 pro-
tein expression had a tendency to accept neoadjuvant chemo-
therapy. Moreover, upregulation of CEP55 protein expression
was significantly associated with ascites see tumor cells,
which is one of the indications for accepting neoadjuvant che-
motherapy. In a more detailed analysis of survival, we ob-
served a significant correlation between shorter OS and high
CEP55 expression in the subgroup with neoadjuvant chemo-
therapy. This finding suggests that CEP55 may be a useful
prognostic marker for ovarian cancer patients with neoadju-
vant chemotherapy.
Primary cytoreductive surgery and adjuvant chemotherapy
are standard treatments for advanced ovarian cancer [33]. In
our cohort, patients with high expression of CEP55 protein
showed a significant tendency to obtain cytoreductive surgery.
Furthermore, we found that higher CEP55 protein expression
was correlated with a significantly shorter OS in the
cytoreductive surgery subgroup. However, no correlation
was observed in the subgroup without cytoreductive surgery.
This result indicates that CEP55 protein expression is a more
significant predictor of prognosis for ovarian cancer patients
who require cytoreductive surgery. Currently, postoperative
chemotherapy is the main treatment for ovarian cancer pa-
tients who have been treated with cytoreductive surgery. Our
study identified a significant correlation between shorter OS
and high CEP55 expression in the postoperative chemothera-
py subgroup. This finding suggests that CEP55 may be a
useful prognostic marker for ovarian cancer patients with
postoperative chemotherapy. One of the most distinct features
of EOC is the tendency to disseminate into the peritoneal
cavity and remain confined to the peritoneum and intra-
abdominal viscera. The peritoneal barrier enables the targeted
delivery of chemotherapy directly to the peritoneal tumors
[34], which makes it an ideal target for locoregional therapy.
In randomized trials, intraperitoneal therapy following front-
line surgery has shown a significant impact on survival [35].
Fig. 8 Downregulation of
CEP55 repressed cellular motility
and invasion. a Invasive
properties induced by FBS were
analyzed by the Boyden chamber
invasion assay (×200, *P<0.05).
bMobility of cells was measured
by testing the rate of wound
closure at 0, 12, and 24 h (×200)
(*P<0.05)
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Improved long-term results can be achieved in highly selected
patients using cytoreductive surgery in combination with
HIPEC [36]. For advanced ovarian cancer, a curative thera-
peutic approach combining optimal cytoreductive surgery and
HIPEC should be considered as it may achieve long-term
survival in patients with a poor prognosis, even in those with
chemoresistant disease [37]. Here, our data showed that pa-
tients with high CEP55 protein expression did not have a
significant tendency to receive HIPEC. However, a significant
correlation was found between higher CEP55 expression and
shorter OS in the HIPEC subgroup, which indicates that
CEP55 expression is an important prognostic factor of ovarian
cancer patients who accept HIPEC.
Conclusions
In this cohort, we demonstrated the upregulated expression of
CEP55 in EOC cells and surgical specimens and reported, for
the first time, the correlation of CEP55 protein expression
with clinical stage, lymph nodemetastasis, intraperitoneal me-
tastasis, tumor recurrence, differentiation grade, residual tu-
mor size, ascites see tumor cells, serum CA153 level, as well
as prognosis in patients with EOC. Patients with aberrant
CEP55 protein expression showed tendencies to receive neo-
adjuvant chemotherapy and cytoreductive surgery. Moreover,
CEP55 may induce ovarian cancer lymph node metastasis
through regulating EMT. Taken together, our results suggest
that CEP55 may be a marker predicting unfavorable outcomes
in ovarian carcinoma and plays a significant role in the migra-
tion and invasion of human EOC.
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